[go: up one dir, main page]

SG11201901712YA - Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors - Google Patents

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Info

Publication number
SG11201901712YA
SG11201901712YA SG11201901712YA SG11201901712YA SG11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA SG 11201901712Y A SG11201901712Y A SG 11201901712YA
Authority
SG
Singapore
Prior art keywords
monrovia
xencor
lemon
west
international
Prior art date
Application number
SG11201901712YA
Inventor
Matthew Bernett
Gregory Moore
John Desjarlais
Michael Hedvat
Christine Bonzon
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en
Publication of SG11201901712YA publication Critical patent/SG11201901712YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIPO I PCT omit °nolo olomum m11°111E11 oimIE (10) International Publication Number WO 2018/045110 Al \". 0.39 = 0.58 RI= 0.313 Ft 2 = 0.61 • Bladder • Breast • Cobn a Head & Neck • Kidney • Lung-Aden • Lung Squamout • Ovarian Pancreatic Prostate • Melanoma Log PD1 mRNA (51) International Patent Classification: C07K 16/46 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/049497 (22) International Filing Date: 30 August 2017 (30.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/381,239 30 August 2016 (30.08.2016) US 62/456,033 07 February 2017 (07.02.2017) US 62/479,723 31 March 2017 (31.03.2017) US 15/623,314 14 June 2017 (14.06.2017) US (71) Applicant: XENCOR, INC. [US/US]; 111 West Lemon Avenue, Monrovia, CA 91016 (US). (72) Inventors: BERNETT, Matthew; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). MOORE, Gregory; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). DESJARLAIS, John; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). HEDVAT, Michael; C/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). BON- ZON, Christine; C/o Xencor, Inc., 111 West Lemon Av- enue, Monrovia, CA 91016 (KH). (74) Agent: NGUYEN, Louis, T. et al.; Morgan, Lewis & Bock- ius, Llp, One Market, Spear Street Tower, San Francisco, CA 94105 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RE- CEPTORS Figure 1 CRICIII I O ;2 (57) : The present invention is directed to bispedfic, heterodimeric immunomodulatory antibodies.
SG11201901712YA 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors SG11201901712YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies
PCT/US2017/049497 WO2018045110A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Publications (1)

Publication Number Publication Date
SG11201901712YA true SG11201901712YA (en) 2019-03-28

Family

ID=65632988

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901712YA SG11201901712YA (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Country Status (12)

Country Link
EP (1) EP3507306B1 (en)
JP (2) JP7080219B2 (en)
KR (2) KR20230130174A (en)
CN (1) CN110267990B (en)
AU (1) AU2017321625A1 (en)
CA (1) CA3035343A1 (en)
DK (1) DK3507306T3 (en)
HR (1) HRP20251424T1 (en)
IL (1) IL265046B2 (en)
MX (1) MX2023006786A (en)
SG (1) SG11201901712YA (en)
ZA (1) ZA201901752B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174012A1 (en) * 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
KR102170077B1 (en) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Specific monoclonal antibody against autocatalytic loop portion of PRSS14/ST14 and use thereof
IL321750A (en) * 2018-10-31 2025-08-01 Bioatla Llc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN115698075A (en) * 2020-04-14 2023-02-03 葛兰素史密斯克莱知识产权发展有限公司 Combination therapy of cancer involving anti-ICOS and anti-PD 1 antibodies, optionally further involving anti-TIM 3 antibodies
AU2021257570A1 (en) * 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CN116615442A (en) * 2020-09-08 2023-08-18 优特力克斯有限公司 Programmed cell death 1 polypeptide variants
CN114195900B (en) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 Anti-4-1 BB/PD-L1 bispecific antibody and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
HRP20170908T1 (en) * 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag ANTI-PD-L1 ANTIBODIES AND THEIR USE TO IMPROVE T-STATION FUNCTION
CN103282385A (en) * 2010-11-12 2013-09-04 美国洛克菲勒大学 Fusion proteins for HIV therapy
UY34887A (en) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
DK2943511T3 (en) * 2013-01-14 2019-10-21 Xencor Inc NEW HETERODIMERIC PROTEINS
DK2970486T3 (en) * 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
RU2727836C2 (en) * 2013-07-25 2020-07-24 Сайтомкс Терапьютикс, Инк. Multispecific antibodies, multispecific activated antibodies and methods of their application
DK3089994T3 (en) * 2013-12-30 2022-07-04 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
EP3206711B1 (en) * 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3789399A1 (en) * 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN107406512A (en) * 2014-11-26 2017-11-28 Xencor公司 With reference to CD3 and CD38 heterodimeric antibodies
HUE048532T2 (en) * 2015-01-08 2020-07-28 BioNTech SE Agonistic tnf receptor binding agents
JP2018503399A (en) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー Multispecific immunomodulatory antigen-binding construct
MA41414A (en) * 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS

Also Published As

Publication number Publication date
KR102575681B1 (en) 2023-09-08
IL265046B2 (en) 2025-04-01
IL265046A (en) 2019-04-30
IL265046B1 (en) 2024-12-01
DK3507306T3 (en) 2025-10-20
JP2022111148A (en) 2022-07-29
EP3507306B1 (en) 2025-10-01
CN110267990B (en) 2023-11-07
JP2019529368A (en) 2019-10-17
AU2017321625A1 (en) 2019-04-04
CA3035343A1 (en) 2018-03-08
KR20190044106A (en) 2019-04-29
CN110267990A (en) 2019-09-20
HRP20251424T1 (en) 2025-12-19
EP3507306A1 (en) 2019-07-10
KR20230130174A (en) 2023-09-11
RU2019109147A (en) 2020-10-05
RU2019109147A3 (en) 2021-01-22
JP7080219B2 (en) 2022-06-03
ZA201901752B (en) 2020-09-30
MX2023006786A (en) 2023-06-20

Similar Documents

Publication Publication Date Title
SG11201901712YA (en) Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903302UA (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201809751XA (en) Egfr inhibitor compounds
SG11201907638QA (en) Proteins binding cd33, nkg2d and cd16
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201907253VA (en) Proteins binding bcma, nkg2d and cd16
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201907023UA (en) Method of reducing neutropenia
SG11201807677YA (en) Antibodies to cd40 with enhanced agonist activity
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201900744SA (en) Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
SG11201908456VA (en) Linker units and molecular constructs comprising same